Developer docs
API playgroundTry for free, no card

Search company profiles

EMBL Ventures

Full company profile

uuid000c4k5

Namestring
EMBL Ventures
Legal namestring
EMBL Ventures GmbH
Company typeenum
Private
Founded yearint
2001
Descriptiontext

EMBL Ventures GmbH is a privately held venture capital firm headquartered in Heidelberg, Germany, founded in 2001 to finance and develop life science companies across Europe. The firm invests in companies developing therapeutic treatment modalities, next-generation enabling technology platforms, and diagnostics and medical devices, typically at Series A and later stages. It distinguishes itself through a formalized, longstanding partnership with the European Molecular Biology Laboratory (EMBL) and its technology transfer organization EMBL Enterprise Management Technology Transfer GmbH (EMBLEM), which the firm cites as a structural source of deal flow and diligence access. The firm is led by Managing Directors Dr. Stefan Herr and Dr. Frank Mühlenbeck, with a broader team that includes founding partner Jan Adams and additional managing partners, and operates from two Heidelberg locations (a Boxbergring office and a campus office on Meyerhofstrasse adjacent to EMBL).

The firm generates returns through equity investments in life science companies, with realized exits including ViraTherapeutics' acquisition by Boehringer Ingelheim for EUR 210 million (2018), Luxendo's acquisition by Bruker (2017), and Immatics' NASDAQ listing (2020), alongside portfolio awards such as Scrip's "Licensing Deal of the Year" and the European Mediscience "Emerging Star" (both 2017, for Crescendo Biologics). The active portfolio includes Topas Therapeutics (antigen-specific immune tolerance, with a EUR 40 million Series B total raised by 2021), Allecra Therapeutics (EXBLIFEP, FDA-approved February 2024), Crescendo Biologics (multi-specific immunotherapies, partnered with BioNTech in 2022), and Immatics.

EMBL Ventures employs a sales-led, network-driven go-to-market: deal sourcing is concentrated at the top of the funnel through EMBL/EMBLEM referrals and the partners' scientific network, with hands-on operational support provided directly to portfolio companies. The firm's value proposition rests on capital, scientific expertise, EMBL ecosystem access, and operational assistance through clinical, regulatory, and exit milestones. Distribution is direct (equity investment into portfolio companies), and the firm does not sell a product platform. Revenue mechanics are typical of a small European life science VC: management fees on a single or limited number of fund vehicles, plus carried interest crystallized on exits. No public disclosures of AUM, fund size, LP composition, or annual revenue are available.

Short descriptiontext

EMBL Ventures is a Heidelberg-based venture capital firm investing across Europe in life science companies developing therapeutics, enabling technology platforms, and diagnostics/medical devices, leveraging a structural partnership with EMBL and its technology transfer arm EMBLEM for deal flow and diligence.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersHeidelberg, Germany
HQ citystring
Heidelberg
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
life science venture capital, healthcare investment, biotech financing, therapeutics investment, medical device investment
Industry1 code
PRIMARYFSANACAB
Healthcare & Life Sciences Growth Equity
NAICS code2 codes
  • Portfolio Management and Investment Advice52394
  • Portfolio Management and Investment Advice523940
SIC code1 code
  • Investment Advice6282
Product category
Life Science Venture Capital
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Investment Returns
TypeLicensing Royalties
Description

EMBL Ventures generates returns through equity investments in life science companies, with exits via M&A, licensing agreements, and IPOs. The firm participates in funding rounds of portfolio companies and realizes gains upon exit events.

embl-ventures.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

EMBL Ventures is a Heidelberg-based venture capital firm that invests throughout Europe in life science companies developing novel therapeutic treatment modalities, next-generation enabling technology platforms, and innovations in diagnostics and medical devices. The firm provides direct equity investment capital (typically Series A and later), hands-on operational support, and portfolio companies benefit from unique access to the European Molecular Biology Laboratory (EMBL) scientific network through its technology transfer arm EMBLEM.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

EMBL Ventures is a venture capital firm headquartered in Heidelberg, Germany, that provides investment services to life science companies. Rather than offering a unified product platform, the firm operates as an investor supporting portfolio companies across Europe. Their offering encompasses direct investment capital, hands-on operational support, access to their scientific and industry network, and unique proximity to the European Molecular Biology Laboratory (EMBL) ecosystem including its technology transfer organization EMBLEM. The firm focuses on companies developing therapeutic treatment modalities, next-generation enabling technology platforms, and innovations in diagnostics and medical devices.

Product and service1 record
1Life science venture capital investment
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1European Molecular Biology Laboratory (EMBL)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

EMBL Ventures has a close relationship with the European Molecular Biology Laboratory. EMBL is at the forefront of life sciences research, innovation, technology development and transfer. The Laboratory is housed at six sites in Europe (headquarter Heidelberg) and has more than 1,600 staff from 80 nations whose research and expertise cover the whole spectrum of molecular biology.

embl-ventures.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

EMBLEM identifies, protects and commercialises the intellectual property developed in the EMBL-world, from EMBL-alumni and from third parties. EMBLEM's pro-active technology transfer approach facilitates and accelerates the transfer of innovative technology from basic research to industry.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

BioMedPartners is a Switzerland-based VC firm focused on early- and growth-stage life sciences investments across Europe. Comparable as a European life sciences VC with similar stage and therapeutic focus.

TypeDirect peer
Description

Forbion is a leading European life sciences venture capital firm investing in therapeutics and enabling technologies. Directly comparable as a European healthcare-focused VC with multiple funds and similar therapeutic/technology focus to EMBL Ventures.

TypeOthers
Description

EMBLEM is EMBL's technology transfer organization and a close strategic partner of EMBL Ventures. While not a competing VC, EMBLEM is the primary deal-sourcing infrastructure for EMBL Ventures and a key ecosystem participant in commercializing EMBL research.

TypeDirect peer
Description

Kurma Partners is a Paris-based VC firm focused on healthcare and life sciences across Europe. Directly comparable as a European life sciences-only VC investing in therapeutics, diagnostics, and digital health.

5EQT Life Sciences (formerly LSP-Life Sciences Partners)
TypeBroad incumbent
Description

EQT Life Sciences is the life sciences arm of EQT, a large global private equity firm. Comparable as a healthcare/life sciences growth investor but operates with significantly larger AUM and broader geographic reach than EMBL Ventures.

TypeDirect peer
Description

Medicxi is a European life sciences-focused investment firm with offices in Switzerland, the UK, and Italy. Directly comparable as a European life sciences-only VC with therapeutics and platform focus.

TypeBroad incumbent
Description

Boehringer Ingelheim Venture Fund is the corporate VC arm of Boehringer Ingelheim, investing in early-stage life sciences. Comparable as a European life sciences investor with therapeutics focus, though embedded within a large pharmaceutical parent.

TypeRegional player
Description

HTGF is a German public-private venture capital investor focused on technology and life sciences startups. Comparable as a Germany-based early-stage investor, though broader across tech and life sciences than EMBL Ventures' focus.

TypeBroad incumbent
Description

M Ventures is the corporate VC arm of Merck KGaA investing across life sciences, technology, and healthcare. Comparable in European life sciences investing but with broader mandate and corporate backing.

TypeDirect peer
Description

LSP is a Netherlands-based life sciences and healthcare VC firm investing across Europe. Directly comparable as a European life sciences VC with similar therapeutic focus and growth-stage investment approach.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment20 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

EMBL Ventures

Life Science Venture Capitalembl-ventures.com

EMBL Ventures is a Heidelberg-based venture capital firm investing across Europe in life science companies developing therapeutics, enabling technology platforms, and diagnostics/medical devices, leveraging a structural partnership with EMBL and its technology transfer arm EMBLEM for deal flow and diligence.

What EMBL Ventures does

EMBL Ventures GmbH is a privately held venture capital firm headquartered in Heidelberg, Germany, founded in 2001 to finance and develop life science companies across Europe. The firm invests in companies developing therapeutic treatment modalities, next-generation enabling technology platforms, and diagnostics and medical devices, typically at Series A and later stages. It distinguishes itself through a formalized, longstanding partnership with the European Molecular Biology Laboratory (EMBL) and its technology transfer organization EMBL Enterprise Management Technology Transfer GmbH (EMBLEM), which the firm cites as a structural source of deal flow and diligence access. The firm is led by Managing Directors Dr. Stefan Herr and Dr. Frank Mühlenbeck, with a broader team that includes founding partner Jan Adams and additional managing partners, and operates from two Heidelberg locations (a Boxbergring office and a campus office on Meyerhofstrasse adjacent to EMBL).

The firm generates returns through equity investments in life science companies, with realized exits including ViraTherapeutics' acquisition by Boehringer Ingelheim for EUR 210 million (2018), Luxendo's acquisition by Bruker (2017), and Immatics' NASDAQ listing (2020), alongside portfolio awards such as Scrip's "Licensing Deal of the Year" and the European Mediscience "Emerging Star" (both 2017, for Crescendo Biologics). The active portfolio includes Topas Therapeutics (antigen-specific immune tolerance, with a EUR 40 million Series B total raised by 2021), Allecra Therapeutics (EXBLIFEP, FDA-approved February 2024), Crescendo Biologics (multi-specific immunotherapies, partnered with BioNTech in 2022), and Immatics.

EMBL Ventures employs a sales-led, network-driven go-to-market: deal sourcing is concentrated at the top of the funnel through EMBL/EMBLEM referrals and the partners' scientific network, with hands-on operational support provided directly to portfolio companies. The firm's value proposition rests on capital, scientific expertise, EMBL ecosystem access, and operational assistance through clinical, regulatory, and exit milestones. Distribution is direct (equity investment into portfolio companies), and the firm does not sell a product platform. Revenue mechanics are typical of a small European life science VC: management fees on a single or limited number of fund vehicles, plus carried interest crystallized on exits. No public disclosures of AUM, fund size, LP composition, or annual revenue are available.

EMBL Ventures firmographics

Firmographics
Name
EMBL Ventures
Legal name
EMBL Ventures GmbH
Website
https://embl-ventures.com
Company type
Private
Founded year
2001
Operating status
Operating
Headcount range
1–10 employees
Short description
EMBL Ventures is a Heidelberg-based venture capital firm investing across Europe in life science companies developing therapeutics, enabling technology platforms, and diagnostics/medical devices, leveraging a structural partnership with EMBL and its technology transfer arm EMBLEM for deal flow and diligence.
Ownership category
akta.pro rank

EMBL Ventures industry classification

Industry
Product category
Life Science Venture Capital
NAICS
Portfolio Management and Investment Advice (52394), Portfolio Management and Investment Advice (523940)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANACAB
Healthcare & Life Sciences Growth Equity

Keywords

  • Life science venture capital
  • Healthcare investment
  • Biotech financing
  • Therapeutics investment
  • Medical device investment

Where EMBL Ventures is headquartered

Location

Headquarters

HQ city
Heidelberg
HQ country
Germany
HQ region
Europe

Offices2 records

Markets served

EMBL Ventures business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Investment Returns: EMBL Ventures generates returns through equity investments in life science companies, with exits via M&A, licensing agreements, and IPOs. The firm participates in funding rounds of portfolio companies and realizes gains upon exit events.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

EMBL Ventures product offering

Product offering

Core offering

EMBL Ventures is a Heidelberg-based venture capital firm that invests throughout Europe in life science companies developing novel therapeutic treatment modalities, next-generation enabling technology platforms, and innovations in diagnostics and medical devices. The firm provides direct equity investment capital (typically Series A and later), hands-on operational support, and portfolio companies benefit from unique access to the European Molecular Biology Laboratory (EMBL) scientific network through its technology transfer arm EMBLEM.

Product overview

EMBL Ventures is a venture capital firm headquartered in Heidelberg, Germany, that provides investment services to life science companies. Rather than offering a unified product platform, the firm operates as an investor supporting portfolio companies across Europe. Their offering encompasses direct investment capital, hands-on operational support, access to their scientific and industry network, and unique proximity to the European Molecular Biology Laboratory (EMBL) ecosystem including its technology transfer organization EMBLEM. The firm focuses on companies developing therapeutic treatment modalities, next-generation enabling technology platforms, and innovations in diagnostics and medical devices.

Differentiator

Problem solved

Functional benefit

Products and services

  • Life science venture capital investment

Companies that use EMBL Ventures

Customer profile

Segments1 record

Ideal customer profiles1 record

EMBL Ventures technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

EMBL Ventures partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • European Molecular Biology Laboratory (EMBL)coreStrategic or Co-development PartnerEMBL Ventures has a close relationship with the European Molecular Biology Laboratory. EMBL is at the forefront of life sciences research, innovation, technology development and transfer. The Laboratory is housed at six sites in Europe (headquarter Heidelberg) and has more than 1,600 staff from 80 nations whose research and expertise cover the whole spectrum of molecular biology.
  • EMBL Enterprise Management Technology Transfer GmbH (EMBLEM)coreStrategic or Co-development PartnerEMBLEM identifies, protects and commercialises the intellectual property developed in the EMBL-world, from EMBL-alumni and from third parties. EMBLEM's pro-active technology transfer approach facilitates and accelerates the transfer of innovative technology from basic research to industry.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

EMBL Ventures competitors and assessment

Company assessment

Direct peers

  • BioMedPartners: BioMedPartners is a Switzerland-based VC firm focused on early- and growth-stage life sciences investments across Europe. Comparable as a European life sciences VC with similar stage and therapeutic focus.
  • Forbion: Forbion is a leading European life sciences venture capital firm investing in therapeutics and enabling technologies. Directly comparable as a European healthcare-focused VC with multiple funds and similar therapeutic/technology focus to EMBL Ventures.
  • Kurma Partners: Kurma Partners is a Paris-based VC firm focused on healthcare and life sciences across Europe. Directly comparable as a European life sciences-only VC investing in therapeutics, diagnostics, and digital health.
  • Medicxi: Medicxi is a European life sciences-focused investment firm with offices in Switzerland, the UK, and Italy. Directly comparable as a European life sciences-only VC with therapeutics and platform focus.
  • Life Sciences Partners (LSP): LSP is a Netherlands-based life sciences and healthcare VC firm investing across Europe. Directly comparable as a European life sciences VC with similar therapeutic focus and growth-stage investment approach.

Others

  • EMBL Enterprise Management Technology Transfer GmbH (EMBLEM): EMBLEM is EMBL's technology transfer organization and a close strategic partner of EMBL Ventures. While not a competing VC, EMBLEM is the primary deal-sourcing infrastructure for EMBL Ventures and a key ecosystem participant in commercializing EMBL research.

Broad incumbents

  • EQT Life Sciences (formerly LSP-Life Sciences Partners): EQT Life Sciences is the life sciences arm of EQT, a large global private equity firm. Comparable as a healthcare/life sciences growth investor but operates with significantly larger AUM and broader geographic reach than EMBL Ventures.
  • Boehringer Ingelheim Venture Fund: Boehringer Ingelheim Venture Fund is the corporate VC arm of Boehringer Ingelheim, investing in early-stage life sciences. Comparable as a European life sciences investor with therapeutics focus, though embedded within a large pharmaceutical parent.
  • M Ventures: M Ventures is the corporate VC arm of Merck KGaA investing across life sciences, technology, and healthcare. Comparable in European life sciences investing but with broader mandate and corporate backing.

Regional players

  • High-Tech Gründerfonds (HTGF): HTGF is a German public-private venture capital investor focused on technology and life sciences startups. Comparable as a Germany-based early-stage investor, though broader across tech and life sciences than EMBL Ventures' focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks4 records

Key highlights6 records

Customer concentration

EMBL Ventures financial estimates

Financial estimate

Revenue estimate

Valuation estimate

EMBL Ventures leadership team

Management profile

Number of profiles

Profiles8 records

EMBL Ventures funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

EMBL Ventures M&A and investment

M&A and investment

M&A

Investments20 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about EMBL Ventures

What does EMBL Ventures do?

EMBL Ventures is a Heidelberg-based venture capital firm that invests throughout Europe in life science companies developing novel therapeutic treatment modalities, next-generation enabling technology platforms, and innovations in diagnostics and medical devices. The firm provides direct equity investment capital (typically Series A and later), hands-on operational support, and portfolio companies benefit from unique access to the European Molecular Biology Laboratory (EMBL) scientific network through its technology transfer arm EMBLEM.

Is EMBL Ventures a public or private company?

EMBL Ventures is a private company. It is classified as management employee owned and is currently operating.

When was EMBL Ventures founded?

EMBL Ventures was founded in 2001. It employs 1 to 10 people.

Where is EMBL Ventures based?

EMBL Ventures is headquartered in Heidelberg, Germany, in the Europe region.

How does EMBL Ventures make money?

One revenue line is on record: investment Returns.

Who are EMBL Ventures's main competitors?

Direct peers on record are BioMedPartners, Forbion, Kurma Partners, Medicxi and Life Sciences Partners (LSP). EMBL Enterprise Management Technology Transfer GmbH (EMBLEM) is listed as an others. Broad incumbents are EQT Life Sciences (formerly LSP-Life Sciences Partners), Boehringer Ingelheim Venture Fund and M Ventures. High-Tech Gründerfonds (HTGF) is listed as a regional player.

Does EMBL Ventures have an API?

No public API is recorded for EMBL Ventures.

What industry is EMBL Ventures in?

EMBL Ventures's product category is Life Science Venture Capital. Its primary akta.pro industry code is FSANACAB, Healthcare & Life Sciences Growth Equity. Its NAICS code is 52394 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireEMBL Ventures Portfolio Company, ViraTherapeutics, Acquired by Boehringer Ingelheim in EUR 210 Million (USD 245 Million) TransactionBoehringer Ingelheim has exercised its option to acquire ViraTherapeutics, a portfolio company of EMBL Ventures, in a transaction valued at EUR 210 million (USD 245 million). The acquisition follows a collaboration and option agreement signed between the two entities in August 2016. ViraTherapeutics will operate as a distinct unit within Boehringer Ingelheim's Discovery Research organization.PR NewswireEMBL Ventures Portfolio Company, ViraTherapeutics Acquired by Boehringer Ingelheim in EUR 210 Million (USD 245 Million) TransactionBoehringer Ingelheim has acquired ViraTherapeutics, a portfolio company of EMBL Ventures, for EUR 210 million (USD 245 million). This acquisition follows a collaboration agreement from August 2016, highlighting the successful partnership between the companies focused on innovative cancer immunotherapy. ViraTherapeutics will continue its operations in Innsbruck under Boehringer Ingelheim's Discovery Research organization.FinSMEsViraTherapeutics Raises €3.6M in First Closing of Series A Financing - FinSMEsViraTherapeutics, an Austrian biopharmaceutical company, raised €3.6M in its first Series A financing round, co-led by Boehringer Ingelheim Venture Fund and EMBL Ventures. The funds will advance its lead product VSV-GP through pre-clinical studies before Phase 1b testing, with first clinical trials expected in 2017.PR NewswireViraTherapeutics Raises €3.6 Million in the First Closing of a Series A Financing Round to Advance its Novel Oncolytic Virus PlatformViraTherapeutics raised €3.6 million in a Series A round co-led by Boehringer Ingelheim Venture Fund and EMBL Ventures. The funds will advance its oncolytic virus VSV-GP through preclinical studies toward Phase 1b trials, with first clinical trials expected in 2017.FinSMEsCrescendo Biologics Raises Further £2M in Series A FinancingCrescendo Biologics raised a further £2M from EMBL Ventures, closing its Series A financing. The round now totals £19.5M, led by Imperial Innovations with participation from Astellas Venture Management and Sofinnova Partners. The company will use the funds to advance its in-house development programmes for psoriasis and oncology indications.